Florbetaben f-18
Looking up MedlinePlus…
From MedlinePlus, U.S. National Library of Medicine
Radioactive Diagnostic Agent
Dosing in kidney impairment
| Organ/Tissue | Mean Absorbed Radiation Dose per Unit Administered Activity [microGy/MBq] |
| Adrenals | 13 |
| Brain | 13 |
| Breasts | 7 |
| Gallbladder Wall | 137 |
| Heart Wall | 14 |
| Kidneys | 24 |
| Liver | 39 |
| Lower Large Intestine-Wall | 35 |
| Lungs | 15 |
| Muscle | 10 |
| Osteogenic Cells | 15 |
| Ovaries | 16 |
| Pancreas | 14 |
| Red Marrow | 12 |
| Skin | 7 |
| Small Intestine | 31 |
| Spleen | 10 |
| Stomach Wall | 12 |
| Testes | 9 |
| Thymus | 9 |
| Thyroid | 8 |
| Upper Large Intestine-Wall | 38 |
| Urinary Bladder Wall | 70 |
| Uterus | 16 |
| Total Body | 11 |
| Effective Dose (microSv/MBq) | 19 |
| Organ/Tissue | Mean Absorbed Radiation Dose per Unit Administered Activity [microGy/MBq] |
| Adrenals | 13 |
| Brain | 13 |
| Breasts | 7 |
| Gallbladder Wall | 137 |
| Heart Wall | 14 |
| Kidneys | 24 |
| Liver | 39 |
| Lower Large Intestine-Wall | 35 |
| Lungs | 15 |
| Muscle | 10 |
| Osteogenic Cells | 15 |
| Ovaries | 16 |
| Pancreas | 14 |
| Red Marrow | 12 |
| Skin | 7 |
| Small Intestine | 31 |
| Spleen | 10 |
| Stomach Wall | 12 |
| Testes | 9 |
| Thymus | 9 |
| Thyroid | 8 |
| Upper Large Intestine-Wall | 38 |
| Urinary Bladder Wall | 70 |
| Uterus | 16 |
| Total Body | 11 |
| Effective Dose (microSv/MBq) | 19 |
Preparation and administration
Prepare this dose
Your numbers for florbetaben f-18. Take vial strength, diluent, and limits from the label below.
Enter a dose to see draw volume, final concentration, and rates.
Recommended Dosing and Administration Instructions Recommended Dosage The recommended amount of radioactivity of NEURACEQ is 300 MBq (8.1 mCi) in a total volume of up to 10 mL, administered as a single slow intravenous bolus (6 sec/mL). The maximum mass dose is 30 micrograms. Follow the administration with an intravenous flush of approximately 10 mL of 0.9% sodium chloride injection.
Patient Preparation Instruct patients to hydrate before and after NEURACEQ administration and to void before imaging and frequently thereafter following NEURACEQ administration [see Warnings and Precautions ] . Administration Use aseptic technique and radiation shielding to withdraw and administer NEURACEQ. Visually inspect NEURACEQ for particulate matter and discoloration prior to administration.
Do not use NEURACEQ if it contains particulate matter or if it is discolored. Do not dilute NEURACEQ. Measure the activity of NEURACEQ with a dose calibrator immediately prior to injection. Verify patency of the indwelling catheter by a test flush with 0.9% sodium chloride injection prior to administration of NEURACEQ. Dispose of unused product in a safe manner in compliance with applicable regulations
Recommended Dosing and Administration Instructions Recommended Dosage The recommended amount of radioactivity of NEURACEQ is 300 MBq (8.1 mCi) in a total volume of up to 10 mL, administered as a single slow intravenous bolus (6 sec/mL). The maximum mass dose is 30 micrograms. Follow the administration with an intravenous flush of approximately 10 mL of 0.9% sodium chloride injection.
Patient Preparation Instruct patients to hydrate before and after NEURACEQ administration and to void before imaging and frequently thereafter following NEURACEQ administration [see Warnings and Precautions ] . Administration Use aseptic technique and radiation shielding to withdraw and administer NEURACEQ. Visually inspect NEURACEQ for particulate matter and discoloration prior to administration.
Do not use NEURACEQ if it contains particulate matter or if it is discolored. Do not dilute NEURACEQ. Measure the activity of NEURACEQ with a dose calibrator immediately prior to injection. Verify patency of the indwelling catheter by a test flush with 0.9% sodium chloride injection prior to administration of NEURACEQ. Dispose of unused product in a safe manner in compliance with applicable regulations
Contraindications
None None.
Supply and cost
Drug shortage status
Recalls (last 24 months)
Therapeutic equivalence (Orange Book)
Price ladder
Not the price at the counterThese are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.